Meta-analysis of efficacy of Shengjing Capsules (Tablets) in the treatment of oligoasthenospermia

Objective To systematically review the effectiveness of Shengjing Capsules (Tablets) in the treatment of oligoasthenozoospermia.

Methods The random controlled trials (RCT) of Shengjing Capsules (Tablets) in treating oligoasthenospermia in China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (Wanfang Data), China Science and Technology Journal Database(VIP), the Cochrane Library and PubMed were searched by computers, and the search time was from the establishment of the database to August 9, 2022. Literature review was conducted by two researchers according to the search methods, and the literatures were screened for inclusion and exclusion. RevMan 5.4 software was used for meta-analysis.

Results A total of 26 literatures were included, with a total of 2 902 samples. Meta-analysis result show that the total effective rate of trail group treated with Shengjing Capsules (Tablets) was significantly higher than that of the control group(RR=1.41, 95%CI, 1.25 to 1.60, P < 0.000 01), and the improvementsin semen volume (MD=0.50, 95%CI, 0.30 to 0.71, P < 0.000 01), semen density(MD=12.39, 95%CI, 9.19 to15.59, P < 0.000 01), sperm rate ofgrade a (MD=7.24, 95%CI, 4.39 to 10.08, P < 0.000 01) and sperm rate of gradea plus b(MD=9.00, 95%CI, 3.25 to 18.15, P < 0.000 01) were significantly better than those of the control group.

Conclusion Meta-analysis study shows that Shengjing Capsules (Tablets) is effective in the treatment of oligoasthenospermia, but we still need more RCTs with high quality and large samples to provide high-level evidence-based medical data.